# Eradication of H. Pylori Infection With Moxifloxacin

> **NCT05863858** · PHASE3 · COMPLETED · sponsor: **Iyad Naeem Muhammad, PhD** · enrollment: 162 (actual)

## Conditions studied

- Helicobacter Pylori Infection
- Helicobacter Pylori Infection, Susceptibility to

## Interventions

- **DRUG:** Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID
- **DRUG:** Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID

## Key facts

- **NCT ID:** NCT05863858
- **Lead sponsor:** Iyad Naeem Muhammad, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-06-08
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863858, "Eradication of H. Pylori Infection With Moxifloxacin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05863858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*